World-first scientific meeting on new cancer treatment targets


World-first scientific meeting on new cancer treatment targets

Our DNA encodes for about 20,000 different proteins that are the machinery of life. Nearly all new proteins are chemically modified in different ways to control how, when and where they work.

Professor Philip Hogg, Chair of Translational Cancer Research at CTC and Sydney Catalyst, has discovered a new type of chemical modification in proteins that appears to be important for all life forms. He has shown that the modification of allosteric disulphide bonds in proteins is related to cancer.

Allosteric disulphide bonds are being identified in many other biological systems such as blood coagulation, immunity and inflammation. Phil is using his novel findings to develop innovative drugs targeting several of these bonds for new cancer therapies.

Phil recently chaired the first scientific meeting dedicated to this chemical modification in Colorado. This important international meeting was sponsored by the Federation of American Societies for Experimental Biology (FASEB), which represents over 125,000 researchers in 30 scientific societies in the USA and around the world, and is the peak body for biological and medical research in the USA. The meeting is a very significant milestone for Phil and his research field.

He says:

'I am enthusiastic about the research area-of course- but I didn't know how others would view it. But there was a real buzz in the room and lots of terrific feedback. Two prominent researchers from Harvard and Stanford have begun organising the next conference in 2018. If that is a success then it should be ongoing, as the research field will continue to expand.'

5 September 2016